DERMATA THERAPEUTICS INC (DRMA) Stock Earnings & Estimates
USA - NASDAQ:DRMA - US2498455045 - Common Stock
5.1 USD
-0.1 (-1.92%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | |||||||
| EBITDA YoY % growth | -4.469M | -3.173M 29.01% | -7.857M -147.65% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.471M | -3.173M 29.03% | -7.857M -147.63% | -9.675M -23.13% | -8.042M 16.88% | -12.513M -55.60% | N/A 34.07% | N/A -41.27% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -220.80 96.76% | -54.75 75.20% | -89.85 -64.11% | N/A 91.19% | N/A 19.72% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.62 92.05% | -1.53 92.57% | -1.53 66.00% | -1.58 4.76% | -1.59 1.89% | -1.65 -8.00% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -1.793M 44.41% | -2.262M 29.31% | -2.764M -18.14% | -2.894M -63.24% | -2.925M -63.14% | -3.071M -35.75% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -1.66 96.03% | -2.96 | 1.30 | 43.88% |
| Q1 2025 Q2Q % growth | -4.50 36.17% | -4.59 | 0.09 | 1.96% |
| Q4 2024 Q2Q % growth | -20.60 -553.97% | -15.30 | -5.30 | -34.64% |
| Q3 2024 Q2Q % growth | -20.40 -151.85% | -26.93 | 6.53 | 24.24% |
| Q2 2024 Q2Q % growth | -41.80 -342.33% | -38.66 | -3.14 | -8.13% |
| Q1 2024 Q2Q % growth | -7.05 79.30% | -5.51 | -1.54 | -28.00% |
| Q4 2023 Q2Q % growth | -3.15 91.25% | -11.93 | 8.78 | 73.60% |
| Q3 2023 Q2Q % growth | -8.10 83.13% | -9.64 | 1.54 | 15.97% |
| Q2 2023 Q2Q % growth | -9.45 83.59% | -14.08 | 4.63 | 32.86% |
| Q1 2023 Q2Q % growth | -34.05 57.01% | -40.55 | 6.50 | 16.02% |
| Q4 2022 Q2Q % growth | -36.00 42.31% | -48.96 | 12.96 | 26.47% |
| Q3 2022 Q2Q % growth | -48.00 76.74% | -53.86 | 5.86 | 10.87% |
| Q2 2022 Q2Q % growth | -57.60 65.71% | -78.34 | 20.74 | 26.47% |
| Q1 2022 Q2Q % growth | -79.20 | -97.92 | 18.72 | 19.12% |
| Q4 2021 Q2Q % growth | -62.40 | -86.90 | 24.50 | 28.20% |
| Q3 2021 Q2Q % growth | -206.40 | -112.61 | -93.79 | -83.29% |
| Q2 2021 Q2Q % growth | -168.00 | -345.17 | 177.17 | 51.33% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -562.5% | 0% | -466.42% |
| Revenue | N/A | N/A | N/A | N/A |